Importantly, administration of MRT-2359 was claimed to decrease tumor size and induce partial responses in some heavily pretreated patients (https://menafn.com/1107255455/Monte-Rosa-Therapeutics-Announces-Interim-PKPD-And-Clinical-Data-For-MRT-2359-In-Phase-12-Trial-For-MYC-Driven-Solid-Tumors) [24]. The gene discussed is MYC; the disease is neoplasm.